These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12358323)

  • 1. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.
    Humbert M; Deng Z; Simonneau G; Barst RJ; Sitbon O; Wolf M; Cuervo N; Moore KJ; Hodge SE; Knowles JA; Morse JH
    Eur Respir J; 2002 Sep; 20(3):518-23. PubMed ID: 12358323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension.
    Morse JH
    Chest; 2002 Mar; 121(3 Suppl):50S-53S. PubMed ID: 11893684
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.
    Souza R; Humbert M; Sztrymf B; Jaïs X; Yaïci A; Le Pavec J; Parent F; Hervé P; Soubrier F; Sitbon O; Simonneau G
    Eur Respir J; 2008 Feb; 31(2):343-8. PubMed ID: 17959632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
    Abramowicz MJ; Van Haecke P; Demedts M; Delcroix M
    Eur Respir J; 2003 Sep; 22(3):560-2. PubMed ID: 14516151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appetite suppressants and pulmonary hypertension: a long-term risk.
    Prescrire Int; 2006 Oct; 15(85):183. PubMed ID: 17131516
    [No Abstract]   [Full Text] [Related]  

  • 6. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
    Thomson JR; Machado RD; Pauciulo MW; Morgan NV; Humbert M; Elliott GC; Ward K; Yacoub M; Mikhail G; Rogers P; Newman J; Wheeler L; Higenbottam T; Gibbs JS; Egan J; Crozier A; Peacock A; Allcock R; Corris P; Loyd JE; Trembath RC; Nichols WC
    J Med Genet; 2000 Oct; 37(10):741-5. PubMed ID: 11015450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension associated with benfluorex exposure.
    Savale L; Chaumais MC; Cottin V; Bergot E; Frachon I; Prevot G; Pison C; Dromer C; Poubeau P; Lamblin N; Habib G; Reynaud-Gaubert M; Bourdin A; Sanchez O; Tubert-Bitter P; Jaïs X; Montani D; Sitbon O; Simonneau G; Humbert M
    Eur Respir J; 2012 Nov; 40(5):1164-72. PubMed ID: 22523367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.
    Fujiwara M; Yagi H; Matsuoka R; Akimoto K; Furutani M; Imamura S; Uehara R; Nakayama T; Takao A; Nakazawa M; Saji T
    Circ J; 2008 Jan; 72(1):127-33. PubMed ID: 18159113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
    Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
    Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Too late, again?
    Jones NL
    Can Respir J; 2001; 8(3):127-8. PubMed ID: 11420587
    [No Abstract]   [Full Text] [Related]  

  • 11. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
    Archer SL; Djaballah K; Humbert M; Weir KE; Fartoukh M; Dall'ava-Santucci J; Mercier JC; Simonneau G; Dinh-Xuan AT
    Am J Respir Crit Care Med; 1998 Oct; 158(4):1061-7. PubMed ID: 9769261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
    Machado RD; James V; Southwood M; Harrison RE; Atkinson C; Stewart S; Morrell NW; Trembath RC; Aldred MA
    Circulation; 2005 Feb; 111(5):607-13. PubMed ID: 15699281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.
    Sztrymf B; Coulet F; Girerd B; Yaici A; Jais X; Sitbon O; Montani D; Souza R; Simonneau G; Soubrier F; Humbert M
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1377-83. PubMed ID: 18356561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anorexigen-related cardiopulmonary toxicity.
    Gross SB; Lepor NE
    Rev Cardiovasc Med; 2000; 1(2):80-9, 102. PubMed ID: 12457145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine.
    Davis WM; Waters IW
    Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension.
    Kabata H; Satoh T; Kataoka M; Tamura Y; Ono T; Yamamoto M; Huqun ; Hagiwara K; Fukuda K; Betsuyaku T; Asano K
    Respirology; 2013 Oct; 18(7):1076-82. PubMed ID: 23675998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.
    Morse J; Barst R; Horn E; Cuervo N; Deng Z; Knowles J
    J Rheumatol; 2002 Nov; 29(11):2379-81. PubMed ID: 12415595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trends and drug exposures in pulmonary hypertension: an American experience.
    Walker AM; Langleben D; Korelitz JJ; Rich S; Rubin LJ; Strom BL; Gonin R; Keast S; Badesch D; Barst RJ; Bourge RC; Channick R; Frost A; Gaine S; McGoon M; McLaughlin V; Murali S; Oudiz RJ; Robbins IM; Tapson V; Abenhaim L; Constantine G
    Am Heart J; 2006 Sep; 152(3):521-6. PubMed ID: 16923424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
    Atkinson C; Stewart S; Upton PD; Machado R; Thomson JR; Trembath RC; Morrell NW
    Circulation; 2002 Apr; 105(14):1672-8. PubMed ID: 11940546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.